KM Research Hub

LITERATURE

符合新入排标准的活动候选

仅显示 v3 复核后仍在自动处理队列中的候选论文。 共 1883 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42225101无 PMCID2026-Jun0.95The record is a phase III randomized, double-blind, placebo-controlled trial in human oncology (prostate cancer) with a drug-containing intervention (aglatimagene besadenovec plus valacyclovir) and a primary time-to-event efficacy endpoint (disease-free survival). It meets all eligibility criteria for the oncology KM digitization cohort.无 KM 图
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).JCO Glob Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42308452无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42202319无 PMCID2026-May-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.Signal Transduct Target TherPMID 42168151PMC131947362026-May-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Randomized Phase II/III Trial Comparing Hepatectomy, Followed by mFOLFOX6 With Hepatectomy Alone for Liver Metastasis From Colorectal Cancer: Long-Term Results of JCOG0603.J Clin OncolPMID 41564372PMC131857292026-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1::非 KM 图;Figure 2::非 KM 图;Figure 3::森林图/亚组分析图;Figure 4::非 KM 图。PMID 41616224PMC128669542026-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Postoperative Hepatic Arterial Infusion With Oxaliplatin After Surgery of Four or More Colorectal Liver Metastases: A Randomized Phase II Trial.J Clin OncolAI 判定该论文不进入自动 KM 提取:The record is explicitly described as a Phase II trial.PMID 42018958无 PMCID2026-May-200.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42018318PMC131038812026-May-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Acalabrutinib vs chlorambucil plus rituximab in untreated chronic lymphocytic leukemia: A randomized phase 3 Asian study.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42154070无 PMCID2026-May-190.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42134356无 PMCID2026-May-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41855781无 PMCID2026-May-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group.Neuro Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41423745PMC131864692026-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.Int J CancerPMID 41474069PMC129637062026-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial.JAMA Surg疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41779406PMC129616012026-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41854603PMC130034052026-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.JCO Oncol PractPMID 40658913PMC122621642026-May0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。已完成
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.J Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41364813无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41412437无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41422862无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41448362无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Belantamab mafodotin, pomalidomide, and dexamethasone in Japanese patients with RRMM in the phase 3 DREAMM-8 trial.Int J HematolPMID 41493718PMC131717702026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Quality-adjusted progression-free survival analysis of veliparib and carboplatin/paclitaxel compared with chemotherapy alone in patients with newly diagnosed ovarian cancer (VELIA/GOG3005): ancillary analysis of a placebo-controlled, phase 3 randomized trial.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41565553无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41571573无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301).Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41633899无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41763609无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41785639无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.Br J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41832299PMC131331082026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Int J Gynecol CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41861615无 PMCID2026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.Br J Haematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:生活质量量表图;FIGURE 3:生活质量量表图;FIGURE 4:生活质量量表图;FIGURE 5:生活质量量表图。PMID 41912408PMC131765212026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:ROC 图;Fig. 2:森林图/亚组分析图;Fig. 3:森林图/亚组分析图;Extended Data Fig. 1:森林图/亚组分析图;Extended Data Fig. 2:森林图/亚组分析图;另有 1 张未列出。PMID 41942646PMC131903002026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.Hematol OncolPMID 42062177PMC131326742026-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.Blood AdvPMID 41628350PMC131335332026-Apr-280.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41880608无 PMCID2026-Apr-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study).Int J Colorectal DisAI 判定该论文不进入自动 KM 提取:This record describes the design and rationale of a trial, not the results of a completed Phase III RCT.PMID 42026347PMC132368272026-Apr-230.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer: The ORCHESTRA Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41837962PMC129937312026-Apr-210.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41604598无 PMCID2026-Apr-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIG 1.:非 KM 图;FIG 2.:AI 判定为 multi panel km;FIG 3.:森林图/亚组分析图;FIG 4.:AI 判定为 multi panel km。PMID 41802242PMC130757862026-Apr-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41818638无 PMCID2026-Apr-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41974149无 PMCID2026-Apr-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.Lancet疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41974150无 PMCID2026-Apr-180.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.Clin Cancer ResPMID 41678313PMC131276072026-Apr-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.Signal Transduct Target TherPMID 41980919PMC130799092026-Apr-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.Signal Transduct Target TherPMID 41968137PMC130710782026-Apr-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41712876无 PMCID2026-Apr-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.BloodPMID 41490515PMC130774772026-Apr-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.Signal Transduct Target TherPMID 41946687PMC130569842026-Apr-080.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41707170无 PMCID2026-Apr-020.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.Clin Cancer ResPMID 41537702PMC130402092026-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Biopsy-based Basal-luminal Subtyping Classifier in High-risk Prostate Cancer: A Combined Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Phase 3 Trials.Eur Urol OncolPMID 39542826PMC120696482026-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials.Eur Urol Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40312181无 PMCID2026-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图